Podcasts about terns

Erie, Pennsylvania eyes Great Lakes cruise ship calls as the region projects $300 million in economic impact for 2026, though low water levels pose challenges. Carnival opens its 2026 Fun-ternship for 100+ teens across six U.S. homeports. And Holland America launches its 153rd Anniversary Sale with up to 30% off fares and $400 in onboard credit.

On this week's episode, Greg Suvannavejh, Josh Schimmer, Yaron Werber, Sam Fazeli, and special guest Financial Times journalist Oliver Barnes kick off by highlighting the strength of the biotech sector from a public markets perspective, noting the XBI has outperformed the S&P 500 so far this year. The group agrees biotech is in a solid position overall. In policy news, the co‑hosts discuss the latest on the Trump administration's proposed 100% pharma tariffs, Most Favored Nation drug pricing, and deals between big pharma and the administration. The conversation shifts to regulatory news, including changes to the CDC's ACIP charter, vaccine oversight concerns, and FDA Commissioner Dr. Marty Makary's press conference highlighting progress under his leadership. The group then highlights major deals, including Merck's $6.7 billion acquisition of Terns and details of the SEC filings, Gilead's $3.15 billion upfront deal for Tubulis, Neurocrine's $2.9 billion purchase of Soleno, and Garda Therapeutics' $125 million acquisition of Assertio. In breaking news, the co-hosts discuss Replimune's second CRL for its melanoma therapy. In data, the group highlights Ascendis' encouraging week‑52 achondroplasia data and Insmed's Phase 2 hidradenitis suppurativa results. The episode concludes with an update on the obesity landscape, including Lilly's newly approved oral GLP‑1, Novo's high‑dose Wegovy, and a Nature paper on GLP‑1 response variability. *This episode aired on April 10.

Studijā bīskaps Kaspars Šterns.

A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury's Paul Bonanos assesses last week's deals by Merck, which is laying out $6.7 billion to acquire Terns, and Gilead, which is buying Ouro for about $1.7 billion up front.Gilead's deal comes as the Foster City, Calif.-based biotech is looking to defend its position in HIV while resetting in inflammation and immunology and growing its oncology footprint through business development. BioCentury's Lauren Martz analyzes the company's pipeline following her recent conversation with CMO Dietmar Berger.Turning to the U.K., Editor in Chief Simone Fishburn details her conversation with CEO of MHRA, Lawrence Tallon, regarding what new reforms in the U.K. mean for drug developers and how he views initiatives helping to build the sector and place the U.K. in the race to become a destination for clinical trials.Rates for the 26th Bio€quity Europe May 4-6 in Prague increase after this week. Register now as a delegate or apply to join the 2026 Presenting Company Class before the conference sells out.View full story: https://www.biocentury.com/article/658974#BiotechMA #BiopharmaStrategy #DrugDevelopment #UKBiotech #ClinicalTrials00:00 - Introduction01:09 - Merck Buying Terns04:31 - Gilead, Galapagos Deal09:35 - Growing Gilead19:20 - Tallon's Vision for U.K. BiotechTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into recent significant advancements and strategic maneuvers reshaping the landscape in these dynamic industries. AstraZeneca has made a notable stride with its chronic obstructive pulmonary disease (COPD) drug candidate, achieving remarkable efficacy in Phase 3 trials. This success is particularly significant given the historical challenges in this therapeutic area, where competitors like Roche and Sanofi have struggled to deliver consistent results. AstraZeneca's achievement not only highlights its innovative clinical development strategies but also offers renewed hope for COPD patients who have long awaited more effective treatment options.In a parallel move, AstraZeneca is pioneering in vivo CAR-T cell therapies, showcasing their potential despite safety concerns following a patient death during trials in China. The therapy's ability to eradicate cancer in three out of five patients underscores its promise as a revolutionary treatment for cancer, illustrating the need for ongoing safety evaluations as this technology develops.Meanwhile, Novartis continues to strategically expand its allergy treatment portfolio with a significant $2 billion acquisition of Excellergy. This deal centers around an anti-IgE program poised to potentially replace Xolair, Novartis's leading allergy medication. Such strategic moves underscore Novartis's commitment to remaining at the forefront of allergy therapeutics by harnessing biotechnological innovations to develop next-generation treatments. This acquisition complements existing assets like Xolair, an IgE blocker now approved for treating food allergies across different age groups, aiming to bolster Novartis's competitive edge in allergy therapeutics by providing a broader array of solutions.Otsuka Pharmaceutical is also making waves with its $1.2 billion acquisition of Transcend Therapeutics. This acquisition focuses on an MDMA analog for psychiatric conditions, marking Otsuka's deepening interest in mental health therapeutics and the burgeoning field of psychedelic compounds as viable psychiatric treatments. This move reflects a broader industry trend towards exploring unconventional therapeutic avenues to address complex mental health issues.On the regulatory front, Takeda is undergoing significant restructuring efforts aimed at achieving $1.3 billion in annual savings through reorganization. This reflects a broader industry trend towards optimizing operations to enhance efficiency and maintain competitiveness in an ever-evolving market landscape.In another noteworthy development, Rocket Pharmaceuticals has secured accelerated FDA approval for Kresladi, a gene therapy targeting severe leukocyte adhesion deficiency-1. This approval highlights the growing potential of gene therapies to meet unmet medical needs for rare diseases and sets an important precedent for other companies seeking expedited regulatory pathways for their gene therapy pipelines.In Alzheimer's research, both Eisai and Alzheon have made significant contributions, especially regarding high-risk patient subsets. Eisai presented real-world data on Leqembi at the AD/PD annual meeting, demonstrating safety and efficacy in patients with specific genetic profiles like APOE4 homozygotes. Concurrently, Alzheon provided insights into its candidate's performance in similar cohorts. These findings underscore personalized medicine's growing importance in neurodegenerative disease treatment.Oncology remains a critical area with Merck's announcement of its planned acquisition of Terns Pharmaceuticals for $6.7 billion. Driven by Terns' promising leukemia drug developments, this acquisition exemplifies how major players are diversifying their oncology pipelines to maintain market leadership amid approaching patent expiraSupport the show

On this week's episode, Grace Colón, Josh Schimmer, Eric Schmidt, and Brian Skorney open with a look at the macro backdrop. With market volatility and interest rate uncertainty, the hosts agree the macro is still “driving the bus,” tempering what might otherwise be stronger bullish sentiment. Even so, biotech continues to demonstrate relative resilience – XBI holding up better than the broader market – reinforcing the view that investors still want to own biotech. In deals, the co-hosts discuss Gilead's more than $2 billion purchase of Ouro Medicines for its autoimmune disease drug, Merck's $6.7 billion takeover of Terns to bolster its oncology pipeline, and Novartis' deal for Exellergy to strengthen its allergy portfolio. The conversation shifts to regulatory news, including the approval of Denali's Hunter syndrome drug, Avlayah, which comes shortly after the FDA rejected Regenxbio's gene therapy for the same condition. Other recent rare disease approvals are noted, with the group interpreting them as signs of slightly increased regulatory flexibility following leadership changes, though uncertainty remains across the health agencies.  The episode concludes with recent data news and market reactions from Sarepta and Arrowhead, Maze versus Vertex in kidney disease, Beam's data in AATD, Lyme disease vaccine data from Pfizer and Valneva, and a preview of data to be presented at AAD. *This episode aired on March 27, 2026. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of transformative events that underscore the dynamic nature of our industry.First on our radar is Merck's acquisition of Terns Pharmaceuticals for a staggering $6.7 billion. This strategic move is rooted in the looming patent expiration of Keytruda, Merck's blockbuster drug. By acquiring Terns, Merck gains access to a promising chronic myeloid leukemia asset, potentially diversifying its oncology portfolio and offsetting anticipated revenue losses. This acquisition is part of a broader industry trend where companies consolidate and acquire to maintain competitive advantages and ensure pipeline robustness amidst patent challenges.In the diabetes arena, Novo Nordisk is making waves with its triple-G candidate in China, which has shown positive mid-phase trial results. This success could position Novo Nordisk as a formidable player in diabetes treatment, even as it faces competition from Eli Lilly. The development not only strengthens Novo Nordisk's global market position but also exemplifies the growing importance of international collaborations and localized clinical trials in accessing emerging markets.Sarepta Therapeutics' investment in Arrowhead Pharmaceuticals' siRNA assets is beginning to show promise with preliminary data from two siRNA candidates. This indicates a significant shift towards RNA-based therapies in addressing untreatable genetic conditions, emphasizing an innovative pivot towards precision medicine and personalized treatment approaches.Maze Therapeutics has released promising phase 2 data for its lead kidney disease candidate, described by analysts as having "best-in-class potential." Despite this clinical promise, the market's negative reaction resulted in a significant drop in Maze's stock value, highlighting the volatile nature of biotech investments where scientific potential often clashes with financial realities.In obesity treatment research, BrightGene's early-stage data shows an 8% weight loss at eight weeks with its oral dual agonist. This adds to evidence supporting multi-target therapies for complex metabolic disorders like obesity. Meanwhile, Takeda's plan to realize $1.3 billion in cost savings through restructuring aims to streamline operations and fund late-stage drug development, reflecting an industry-wide focus on operational efficiency.The partnership between ICON and Advarra seeks to optimize clinical trial efficiency through a network of connected sites, aligning with broader industry efforts to leverage technology and improve drug development timelines.Turning to UCB's substantial $2 billion investment in a biologics manufacturing facility near its US headquarters in Atlanta, Georgia, this move marks UCB's first major manufacturing footprint in the United States, underscoring its commitment to expanding biologics production capabilities. Biologics are increasingly important due to their potential for treating chronic and genetic conditions, highlighting why UCB's investment is pivotal as it strengthens its position in the US market.Biogen's collaboration with Alteogen involves a $20 million investment to utilize Alteogen's subcutaneous delivery technology for two unnamed biologics. Subcutaneous administration offers improved patient convenience and potentially better therapeutic outcomes compared to traditional intravenous methods.On the regulatory front, ImmunityBio received an FDA warning over promotional claims for Anktiva, their cancer drug. This underscores the critical need for accurate communication in drug marketing. Additionally, CSL updated its Flucelvax label at the FDA's request to include a febrile seizure warning, reflecting ongoing vigilance in post-marketing surveillance.The integration of AI into pharmaceutical operations is accelSupport the show

Conti record a Piazza Affari con Fincantieri e primo utile storico per Ita Airways. Sul fronte M&A, Mondadori punta alla scolastica di Hoepli mentre Merck rafforza l'oncologia con un'Opa miliardaria su Terns. Focus anche sul tech: Sk Hynix prepara lo sbarco a Wall Street per cavalcare il boom della domanda di chip legati all'intelligenza artificiale. Learn more about your ad choices. Visit megaphone.fm/adchoices

US equity markets advanced amid hopes of a ceasefire in the US-Iran war - Dow +305-points or +0.66%. Sherwin-Williams Co (+2.63%) and Merck & Co Inc (+2.58%) climbing over >2.5%. The latter announced that it will acquire US biotech firm Terns Pharmaceuticals for US$53 per share in cash, valuing the company at ~US$6.7B. Terns is developing TERN-701, an oral therapy for chronic myeloid leukemia. It marks Merck's third multibillion-dollar acquisition in the past year as the company looks to strengthen its portfolio ahead of its top-selling cancer drug Keytruda losing patent protection in 2028.

Your questions kept coming! Dr Claire Greenwell returns to answer listener questions about leg colour, juvenile plumage, and how to photograph fast-moving seabirds with confidence.

Australia's terns are fast, fascinating and full of subtle differences. Dr Claire Greenwell shares how to tell Fairy Terns from Little Terns, what makes seabirds so unique and why community action is critical for their conservation.

The Farne Islands in the North Sea, off the coast of Northumberland, have a very special species of seabird during the summer that fiercely protects its young with its dive-bombing technique. However, it's the Arctic Terns' ability to fly thousands of miles during their migration from the Arctic Circle to the Antarctic Circle that really sets them apart.  Join Rosie and Rangers Dan Iceton and Tom Hendry on Inner Farne as they spend time with the Arctic Terns and experience their dive-bombing tactics first-hand.   [Ad] Wild Tales is sponsored by Cotswold Outdoor, your outside retailer and epic guides to adventure.   Quick breathers, calming walks or heart-pounding hikes. We feel better when we get out more.   Find quality kit and 50 years of outdoor wisdom. Plus, supporters save 15% in-store and online. Feel in your element, in the elements, at Cotswold Outdoor.  www.cotswoldoutdoor.com/ Watch a video of this podcast on the National Trust's YouTube channel: https://www.youtube.com/@nationaltrustcharity/podcasts  Production:  Hosts: Rosie Holdsworth and Dan Iceton Producer: Katy Kelly  Sound Editor: Jesus Gomez  Contributor: Tom Hendry Discover More:  Find out more about The Farne Islands: Our work at Farne Islands | Northumberland | National Trust Follow us @wildtales Instagram account If you'd like to get in touch with feedback or a story idea you can contact us at podcasts@nationaltrust.org.uk 

Like an expert angler, a tern can read the surface of the water to find where to catch its next fish. Scientists piloted a drone to track the flight paths of terns on the hunt. The terns sought out turbulent water. A vortex formed by colliding currents traps fish near the surface, where terns can snap them up. Terns fly toward bubbly upwellings to see if the rising water brings prey animals along with it.More info and transcript at BirdNote.org.Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We shake it up this week with a philosophical text and some YA, plus a favorite backlist title of Hannah's that Sam experiences for the first time! Also, we get a treatise on the difference between a romance and a love story. This fortnight, we read: "The Rest of our Lives," by Ben Markovits "On Drugs," by Justin Smith-Ruiu "Red as Royal Blood," by Elizabeth Hart "Migrations," by Charlotte McConaghy What sound effects did we give each of these books? You'll just have to listen and find out!

Vinay Prasad is back at the FDA as chief of the FDA's Center for Biologics Evaluation and Research. Prasad's return—which hit the news wires Saturday morning—came just 10 days after his unexpected exit on July 29, following blowback over the saga involving Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, and a campaign by conversative personalities to oust the outspoken physician.Elsewhere in the government, Gray Delany, former head of HHS' and President Donald Trump's Make America Healthy Again agenda, has been fired—days after Health and Human Services Secretary Robert F. Kennedy Jr. axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority. Delany's ouster came after he allegedly butted heads with other agency officials over how announcements were made, according to reporting from Endpoints News. The mRNA contract cuts, meanwhile, have sparked criticism from the scientific community and concern that the growing anti-mRNA sentiment could also have a negative effect on research for cancer therapeutics.In somewhat related news, the Annals of Internal Medicine is refusing to retract a large-scale study it ran in July that pointed to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions, despite Kennedy's criticism. In an op-ed published earlier this month, the Health Secretary took issue with the study's design.In obesity news, biopharma darling Eli Lilly suffered a rare chink in its normally impenetrable GLP-1 armor. The first Phase III trial for oral weight loss therapy orforglipron read out last week, and the results were underwhelming, at least to Wall Street. Truist Securities wrote that the data support approval but “leaves room for competition.” This is good news for a whole host of companies, including Roche, Viking, Terns and Rhythm Pharmaceuticals, who all have weight loss pills at various stages of development.And in gene therapy, the hits just keep coming. The FDA has limited the use of bluebird bio's gene therapy Skysona to patients with cerebral adrenoleukodystrophy for whom no other therapies or stem cell donors are available, due to a heightened risk of blood cancers. This follows safety issues in gene therapy trials experienced by Allogene, and, of course, Sarepta Therapeutics. This week in ClinicaSpace, Dan Samorodnitsky explored the future of AAV technology. And in BioPharm Executive, Annalee Armstrong sat down with Chris Anzalone, CEO of Arrowhead Pharmaceuticals—Sarepta's key strategic partner—to learn how his company has been weathering the storm.

In June of 2022, Adé Ben-Salahuddin worked as a volunteer research assistant on a tiny island off the coast of Maine at a Common Tern breeding colony. Every once in a while, the colony would suddenly go dead silent as all the adult terns took flight and dove over the rocky cliffs, returning soon afterward. This strange behavior is called a “dread,” and sometimes occurs without a predator nearby. It remains unclear why terns do it.More info and transcript at BirdNote.org.Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.

Synopsis: Amy Burroughs, CEO of Terns Pharmaceuticals, joins Alok Tayi to share how she's leading bold innovation in CML and obesity treatment, driving two high-stakes data readouts in 2025. From a non-linear path through tech, brand management, and Genentech to building resilient biotech teams, Amy reveals why product positioning, tolerability, and mentorship matter just as much as the science. She also shares her take on CEO loneliness, the value of a “personal board of directors,” and what it takes to lead with clarity, grit, and purpose in today's biotech landscape. Biography: Amy Burroughs joined as our Chief Executive Officer and a member of our Board of Directors in February 2024, bringing more than 25 years of leadership experience. Most recently, she served as CEO at Cleave Therapeutics, where she led the company through financings, spearheaded licensing and collaboration deals, and oversaw the clinical development of its investigational therapy, CB-5339, for the treatment of acute myeloid leukemia. Previously, she served as executive in residence at 5AM Ventures and, in parallel, as senior advisor to one of its portfolio companies, Crinetics Pharmaceuticals, during its initial public offering. Earlier in her career, Ms. Burroughs held roles of increasing responsibility in commercial and strategy at Genentech, commercial and business development at other high growth therapeutics companies, talent and governance at Egon Zehnder International, and brand management at Procter & Gamble. Ms. Burroughs earned her M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and her B.A. in computer science with a minor in economics from Dartmouth College. She is currently a member of the board and audit committees at Tenaya Therapeutics.

Send us a textFrost and drought in the garden and Tom's buzzing after a visit to the Chelsea Flower Show…Tom Cadwallender's taking a 'tern' at volunteering and  listening songbirds… And sustainability is one of Steve Lowe's missions: composting, wormeries and hot bins at the Cresswell Pele Tower…Plus we've got some top tips for the garden from Tom P…Support the showYou can follow Tom Pattinson, Steve and Tom Cadwallender and our wonderful guests and featured flowers, birds and projects on Twitter: @gardenersradio @TheNatureGarden and on Facebook: The Nature Garden. And you can tune in to our monthly live radio show on Saturdays at 11am on www.lionheartradio.com Or email us: gardenersradio@outlook.comThank you for your support!Music link: Gaia by Carl Cape Band on Amazon Music - Amazon.co.uk

Eduardo Esquenazi is the founder of Terns, a company dedicated to merging outdoor adventure with sustainable innovation. A lifelong angler and waterman, his deep passion for fishing drives his mission to create eco-conscious solutions that protect the waters he loves. In this episode of Anchored, we dive into biology and explore a topic often overlooked—the importance of self-care for anglers in the outdoors. As it turns out, the solution may have been right under our rod tip all along… This episode of Anchored is brought to you by BetterHelp. On Anchored, we dive deep into conversations about the outdoors, personal growth, and the challenges that come with both. One topic that comes up time and time again is mental health—because let's be honest, life can be tough, and the stresses of work, relationships, and even the activities we love can take a toll. Whether it's managing anxiety, dealing with burnout, or simply striving for a better sense of balance, taking care of your mind is just as important as taking care of your body. Therapy isn't just for people in crisis—it's a powerful tool for building resilience, setting boundaries, and developing positive coping strategies. Traditional in-person therapy can cost up to $250 per session, but with BetterHelp, you can save up to 50% while getting professional support from the world's largest online therapy platform. With over 30,000 therapists and the flexibility to switch providers anytime, BetterHelp makes therapy more accessible and convenient. Your well-being is worth investing in. Visit BetterHelp.com/ANCHORED today to get 10% off your first month. That's Better H-E-L-P dot com slash ANCHORED. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textWelcome to this week's episode of "Laundromat News Today" I'm your anchor, Jordan Berry, bringing you the latest in laundromat industry news. In today's episode, we start on a somber note, paying tribute to Keenan, a beloved figure in our community who has recently passed away. We'll also delve into the cost comparison between doing laundry at home versus at a laundromat and spotlight a significant robbery in Canada. On a brighter side, we explore some innovative solutions like the solar panel initiative by Troy Laundromat to combat rising utility costs. Finally, we wrap up with a huge industry announcement: Pay Range has acquired Terns, and we preview an upcoming episode that will further discuss this major merger with insights from Sukanth.Stay tuned for all this and more on Laundromat Resource!Connect With UsYouTubeInstagramFacebookLinkedInTwitterTikTokConnect With UsYouTubeInstagramFacebookLinkedInTwitterTikTokConnect With UsYouTubeInstagramFacebookLinkedInTwitterTikTok

Like an expert angler, a tern can read the surface of the water to find where to catch its next fish. Scientists piloted a drone to track the flight paths of terns on the hunt. The terns sought out turbulent water. A vortex formed by colliding currents traps fish near the surface, where terns can snap them up. Terns fly toward bubbly upwellings to see if the rising water brings prey animals along with it.More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Amazon has partnered with Talkspace to expand its digital health benefits program, which also includes Omada Health. Community Health Systems (CHS) subsidiary is acquiring 10 urgent care centers, following in the footsteps of other for-profit health systems. Steward Health Care auctioned off Glenwood Regional Medical Center for $500,000, but there are concerns about the continued involvement of hospital landlord Medical Properties Trust in operations. The text also includes sponsored content on safeguarding healthcare against ransomware and cybercrime, as well as information on trends in telehealth and strategies for improving provider data accuracy for payers. Healthcare Dive provides news and insights for healthcare leaders and is a publication operated by Industry Dive.Roivant's subsidiary, Dermavant, is being acquired by Organon, giving Organon access to a psoriasis and eczema cream called Vtama. This acquisition will provide Roivant with additional cash to fund its research and development plans. Meanwhile, biotech M&A activity has plateaued, with private company acquisitions continuing while public company acquisitions have slowed down. One biotech, Ratio Therapeutics, backed by Bristol Myers Squibb, is optimistic about the boom in radiopharma and the pharmaceutical industry's shift towards targeted radiation drugs. In other news, Novartis' Kisqali has received expanded FDA approval which could double its market for breast cancer treatment. Additionally, Express Scripts is suing the FTC over a report critical of pharmacy benefit manager business practices. The industry is also exploring new ways to deliver genetic therapies and improve clinical trial execution through systems thinking. Overall, the biopharma industry is experiencing exciting times with various developments and advancements in drug development and healthcare technology.Zimmer has decided to pull its hip implant off the market due to fracture risk, with plans to phase out its use by December. Merit Medical has acquired Cook's lead management business for $210 million, adding devices used in heart rhythm device procedures to its portfolio. Synchron has connected brain-computer interface technology to Amazon Alexa, allowing patients to control various functions without using their hands or voice. Senseonics has received FDA clearance for a one-year continuous glucose monitoring system, and Boston Scientific has closed its acquisition of Silk Road Medical. The wearables market is expected to grow by 13% annually between 2024 and 2030, highlighting the importance of adhesives in wearable device development. AI is increasingly influencing the value chain of medical device companies, and manufacturers are exploring ways to utilize AI throughout the product lifecycle. These developments reflect the ongoing innovation and evolution within the medtech industry.Roivant has sold Dermavant to Organon in a deal worth up to $1.2 billion, allowing Roivant to focus on their autoimmune-focused Immunovant and upcoming trials. Summit Therapeutics' bispecific for non-small cell lung cancer has shown promise against Keytruda but still needs more data. Other news includes the FDA approving Keytruda for pleural mesothelioma, Bernie Sanders claiming generics companies can offer a cheaper alternative to Ozempic, Novartis expanding Kisqali's use in breast cancer, and HRSA threatening sanctions against J&J. In the world of enzyme development, SignalChem Biotech offers tailored services. Additionally, new gene therapies for sickle cell disease are reaching patients, and the race for an obesity pill is heating up among companies like Novo, Roche, and Terns.The FDA is facing challenges with conducting overseas drug manufacturing inspections, with 42% of registered plants overdue for inspections. Indian drugmaker Zydus Lifesciences received a warnin

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

Summit Therapeutics made headlines this weekend at the 2024 World Conference on Lung Cancer, revealing that its bispecific antibody outperformed Keytruda in first-line non-small cell lung cancer. Meanwhile, bispecifics are one of several therapeutic classes on the agenda at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona later this week. Last week, BioMarin held a public address intended to calm anxious investors after rounds of layoffs and pipeline changes—but many were left wanting. Also undergoing major upheaval is Lykos Therapeutics, which laid off 75% of its workforce after failing to secure approval for its MDMA-based post-traumatic stress disorder therapy and announced last week that CEO Amy Emerson is stepping down from her role. In Washington, D.C., Congress is back in session this week and wasted no time in reviewing the BIOSECURE Act, which passed a House vote on Monday.  And on the weight loss front, Terns Pharmaceuticals is moving ahead to Phase II after its investigational GLP-1 pill elicited positive results in Phase I, and Amgen is pushing MariTide into a broad late-stage development program that will test the obesity treatment in other weight-related conditions, such as heart, kidney and liver diseases.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Candid, a startup, is investing $370 million to prove the worth of bispecifics in autoimmune diseases. Summit's lung cancer drug has shown significant benefits over Keytruda, a popular immunotherapy drug. Relay's breast cancer drug also showed promise in early trials. Biotech IPOs are crucial in the industry, and their performance is being closely monitored. Early study data on Terns, a potential contender in the obesity drug market, is also discussed.Summit Therapeutics has declared victory over Keytruda in advanced non-small cell lung cancer, with their drug Ivonescimab showing a 49% higher effectiveness in reducing disease progression or death in a late-stage study. GSK is set to approach the FDA with positive Phase III data for a long-acting asthma medication. Terns Pharmaceuticals' investigational GLP-1 pill has shown promising weight loss results. Sino Biological has launched a new center for bioprocessing, and various pharmaceutical companies are making advancements in their pipelines. The FDA tracker highlights Travere's full approval for an IgAN drug.The challenges faced in the cell and gene therapy industry as it grows in popularity among investors and innovators are discussed. Shortages of brand-name diabetes and obesity medications from Novo Nordisk and Eli Lilly, such as Ozempic and Mounjaro, are due to high demand. Efforts are being made to ramp up manufacturing and develop new medications. Lilly recently made a billion-dollar deal with Haya Therapeutics to develop genetic obesity medications. The revival of drugs for Huntington's disease after initial trial failures is mentioned. Challenges in turning new drugs into successful assets even after FDA approval are highlighted, along with a poll on which presidential candidate would support policies favorable to the pharma industry. Information on staying compliant with the EU GMP Annex 1 revision is also provided.

Send us a textThis week's episode is packed with the latest updates, insights, and stories from the laundromat industry, both domestically and internationally. In This Episode, We Cover:

Many oceanic species like grebes, loons, pelicans, and gulls migrate far inland to raise their young near freshwater lakes. Ring-billed Gulls, for example, breed throughout the northern U.S. Forster's Terns can be found catching fish in the upper Midwest in the summer. In northern Canada, you may even catch a glimpse of a Surf Scoter as it dives below the glassy surface of the lake. These species return to the coasts for the winter.More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible. 

Eanna Ni Lamhna, Wildlife Expert and author of Wonders of the Wild

Send us a Text Message.Tom Pattinson's getting creative and investing time to propagate plants, Tom Cadwallender's up with the larks for the dawn chorus… and he's super excited on Coquet Island… home of the roseate tern...Steve Lowe's trying his hand at beekeeping at the Creswell Pele Tower garden… And… Dr Zoe Randall from Butterfly Conservation is here to inspire us all to take part in the Big Butterfly CountPlus  some top tips for the garden from Tom P… Support the Show.You can follow Tom Pattinson, Steve and Tom Cadwallender and our wonderful guests and featured flowers, birds and projects on Twitter: @gardenersradio @TheNatureGarden and on Facebook: The Nature Garden. And you can tune in to our monthly live radio show on Saturdays at 11am on www.lionheartradio.com Or email us: gardenersradio@outlook.comThank you for your support!Music link: Gaia by Carl Cape Band on Amazon Music - Amazon.co.uk

Listen to part 1 for this to make sense.

I set the stage for the Boston City Council's fight to overturn Mayor Wu's vetos. Do they succeed? Do they fail? And how does the new class of councilors, many of whom owe their seats to Wu act? Witness the rise of the Wu-terns.

Farming and environmental groups call on politicians to commit to a major increase in funding for the agricultural sector ahead of the General Election. We hear from BBC Wales' Environment correspondent, Steffan Messenger.We hear about the remarkable natural phenomena of insect migration through a Pyrenean mountain pass. Insect migration scientist, Dr Will Leo Hawkes, explains how migrating flies could help in the face of climate change.Rodney's Pillar - an update on the campaign to save an iconic landmark near Llanymynech, on the Welsh border.We escape to the Skerries for our Red listed bird of conservation concern and hear how some very noisy Arctic Terns are faring.

Lira Valencia grew up in Croydon, surrounded by the kind of urban sprawl that keeps the natural world at a distance. However, thanks mostly to the snails in her grandma's garden, she developed a passion for nature and forged a path to a career in the overwhelmingly white world of conservation. We join her for a walk around Walthamstow wetlands, where she's a ranger who helps preserve the habitat and encourage others to enjoy it. Follow Lira on Instagram to see what she spots outside as the seasons turn, or ourselves to see us working on the podcast and discovering great new places.  A Life More Wild is an 18Sixty production, brought to you by Canopy & Stars. Production by Clarissa Maycock and recorded by Marnie Woodmeade. Our theme music is by Billie Marten.

Dede Terns-Thorpe is the historian for the Town of Hunter, referred to locally as "the mountain top," and comprising the villages of Hunter and Tannersville, and the hamlets of Edgewood, Elka Park, Lanesville, and Platte Clove, plus the historic private communities: Onteora Park, Twilight Park, and Elka Park. Dede's passionate about the history of this place, and she's got her own history here, too, which is mostly what we talked about when we met at Tannersville's Mountain Top library. We were joined by Dede's husband Ed, a Mountain Top native with a few stories of his own to share! Photo courtesy Dede Terns-Thorpe --- Thanks to this week's sponsors: Briars & Brambles Books, Hanford Mills Museum, Ulster Savings Bank, and The Mountain Eagle. Kaatscast is made possible through a grant from the Nicholas J. Juried Family Foundation, and through the support of listeners like you! Please rate and review on the podcast app of your choice. Thank you!

"The sound of the migrating terns is replaced by violins playing a the same rhythm as a short loop of the field recording. This pattern is faded in and out with other orchestral string instruments playing similar tern patterns." Migrating terns reimagined by Simon Woods.

Cameron Cox's Terns of North America: A Photographic Guide published by Princeton University Press, is the essential identification guide to the terns, noddies, and skimmers of North America. Covering every species and featuring hundreds of high-quality color images, this book is the ideal companion for anyone interested in this charismatic but sometimes challenging group of seabirds. 

Luc returns from a successful outing at the USN Gathering in Las Vegas, TJ and Luc celebrate Terns arriving in customer hands for the first time.

Russia grain transfer, AI authors letter, Terns avian flu, Darfur mass grave, Perpetual stew and more

We talked about one of the most impressive, and maybe underappreciated, little creatures on the planet... The Arctic Tern! Seabird biologist Bill Montevecchi is tern-ing our attention to these seasonal visitors, who are putting on a spectacular show every night in Conception bay.

The Gull-billed Tern are terns with black caps and unusually thick bills– like a gull. This lets them eat more types of prey than other terns that rely on fish. Gull-billed Terns tackle crabs and lizards on the ground, catch flies, and even steal chicks from other birds. They're found across the coasts of Central and South America and Southeastern US and California. The U.S. Fish and Wildlife Service considers the species a Bird of Conservation Concern due to boating or construction work near their nesting colonies.More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.

In June of 2022, Adé Ben-Salahuddin worked as a volunteer research assistant on a tiny island off the coast of Maine at a Common Tern breeding colony. Every once in a while, the colony would suddenly go dead silent as all the adult terns took flight and dove over the rocky cliffs, returning soon afterward. This strange behavior is called a “dread,” and sometimes occurs without a predator nearby. It remains unclear why terns do it.More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.

We love our Shorebirds! We go on a shorebird survey with DNR biologist Todd Schneider and learn how to recognize difficult to identify shorebirds. For more information about shorebird ID, Click hereTo check out the NERRS I Heart Estuaries Campaign and to follow NERRA, click here. 

As the Apes world Terns, so too do Jack and Geoff as they turn towards the conclusion of Boom! Studios Exile on the POTA! A massive showdown is a-brewin', as Dr. Zaius and his army of the apes square off against General Aleron, Tern, and their sign-languagin' human crew. Is there any hope for Aleron's seemingly ill-fated human experiment? Will the Statue of Liberty serve once again as a beacon of hope to those seeking freedom? Can a Covid-ridden Jack overcome the viral strain being placed upon his voice? Listen on, Ape Faithful!

Michael Ellis looks at seabirds who fly astounding distances.

Today Mary is talking to Dr Stephen Newton. senior Seabird Conservation OfficerStephen is responsible for managing the long-term conservation projects at Rockabill (Roseate Terns), Kilcoole (Little Terns) and a variety of other seabird monitoring and research initiatives, including the FAME and MarPAMM programmes which have focused on deploying loggers on seabirds to identify key feeding areas and migration strategies.Away from seabirds, Stephen has coordinated surveys of Choughs, upland birds and was a member of the team who developed the ‘Birds of Conservation Concern in Ireland' concept back in 1999. He is also Chairperson of the Irish Rare Breeding Birds Panel and in his spare-time is a keen local patch ‘Birdtracker'.Recommended booksCollins Bird GuideBy: Lars SvenssonContact Dr Stephen Newton at info@birdwatchireland.ieFind ways to get involved herehttps://birdwatchireland.ie/get-involved/https://www.bto.org/our-science/projects/birdtrackContact Mary Bermingham atmary@burrennaturesanctuary.ieCheck out Burren Nature Sanctuary at www.burrennaturesanctuary.ieSupport the Nature Magic Podcast athttps://www.patreon.com/naturemagicShow websitewww.naturemagic.ie

The Northeast population of Roseate Terns is endangered. Each summer, roughly twenty-five hundred Roseate Terns are found on Ram Island, a 2.5-acre island off the coast of Massachusetts. In the 1960s and 70s, gull numbers surged. Gulls drove terns off of Ram Island, until biologists began chasing off the gulls to encourage terns to nest there again. Their efforts were successful: today, about one in five Roseate Terns in North America nests on the island. The site is designated as an Important Bird Area (IBA.)More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.

Some gulls and terns may show a glowing pink color, similar to that of flamingos and spoonbills. This pink color comes from pigments in the birds' food called carotenoids. These gulls and terns are able to convert these naturally occurring pigments to hues that may enhance their success at attracting a mate.More info and transcript at BirdNote.org.Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible.

This is Episode 47. It's all about birds in the family Laridae. This is an ancient evolutionary lineage that originated over 70 million years ago, when the world was still ruled by dinosaurs.Besides gulls and terns, the family Laridae also includes the skimmers and the noddies.~~ Leave me a review using Podchaser ~~Links of InterestShoplifting gull stealing Doritos.Link to this episode on the Science of Birds websiteSupport the show (https://www.patreon.com/scienceofbirds)

Jeff Bezos and his brother are being shot into space–who would you take with you? A new study says sighted and nonsighted people can learn functioning echolocation in less than 3 months. Lots of bird eggs, very few birds. With special guest Joe Diamond. Got something weird? Email neshcom@gmail.com, subject line “Weird Things.” Picks: Justin: Mare of Easttown Brian: Kim's Convenience (anti-pick for season 5) Bryce: King of the Hill Joe: Bo Burnham: Inside